SARS-Cov-2

Health care workers with a nasopharyngeal swab positive for SARS-CoV-2 were more likely to report long COVID symptoms after 6 months than negative controls in a study conducted in more than 20 Swiss hospitals.

Convalescent plasma with high neutralizing antibodies produced a strong and rapid viral clearance when administered to patients hospitalized with COVID-19, according to recent data.

Researchers evaluated the immune responses of a few dozen people who received three doses of a COVID-19 messenger RNA vaccine and found, as other have, that a booster shot can protect people infected with a variant from becoming very ill.

A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational monoclonal antibody for the treatment of mild to moderate COVID-19 in a phase 3 trial, investigators reported.

A 27-year-old woman was urgently transferred to Tufts Medical Center, from an outside hospital, for painful worsening facial cellulitis and pansinusitis. Her medical history was notable only for frontal bone fracture in 2001.

Team cohesion and effective employee retention strategies allowed small ophthalmology practices to rise to the challenges of the SARS-CoV-2 pandemic and grow even stronger in some cases.

CDC Director Rochelle P. Walenksy, MD, MPH, had some advice for combating vaccine hesitancy in the United States.

The effectiveness of a COVID-19 booster shot waned over time, but the extra dose continued to protect against hospitalization at 4 months and beyond, according to data collected during the omicron surge and reported Friday in MMWR.

The CDC has begun reporting the proportion of COVID-19 cases in the United States that are caused by the omicron subvariant BA.2.

Prior SARS-CoV-2 infection protects against symptomatic reinfection with SARS-CoV-2 variants, including omicron, national data from Qatar showed.